Workflow
Healthcare Technology
icon
Search documents
Bull Of The Day: OptimizeRX (OPRX)
ZACKS· 2025-07-31 20:01
OptimizeRX (OPRX) is a Zacks Rank #1 (Strong Buy) that has an F for Value and an A for Growth. The company runs a health solutions platform that helps physicians and patients better afford and comply with their medicines and healthcare products. The company is expected to report earnings on 8/7, so now is a great time to take a look at this small cap company. Let's learn more about why this stock is the Bull of the Day. Description Estimates are moving higher for OptimizeRX (OPRX) . The full year 2025 has i ...
Does OptimizeRx Have a Moat in the Crowded HealthTech Space?
ZACKS· 2025-07-31 13:40
Key Takeaways OptimizeRx (OPRX) is carving out a secure niche in the increasingly crowded HealthTech landscape, signaling a developing moat anchored in scale, data and execution. Over the previous two quarters, the company has posted double-digit top-line growth. More importantly, its strategic transition from transactional to subscription- based revenues — now accounting for 5% of 2025's projected revenues — is starting to pay dividends in visibility and margin structure. The company's core strength lies i ...
Clover Health Applauds White House and CMS’ Push to “Tear Down Digital Walls,” Accelerating and Simplifying Access to Health Data for Patients and Their Clinicians
Globenewswire· 2025-07-31 12:30
Outcomes like these, from earlier diagnosis and management of chronic conditions to better medication adherence, contributed to Clover Health PPO plans' 4 Star rating for 2025, including achieving 4.94 out of 5 Stars on HEDIS measures, the top-performing score on core HEDIS measures for Medicare Advantage plans with over 2,000 members nationwide. Clover Health's AI platform, Counterpart Assistant, already connects to a majority of the data networks named in yesterday's pledge – eliminating the "digital wall ...
Waystar Holding Corp.(WAY) - 2025 Q2 - Earnings Call Transcript
2025-07-30 21:32
Financial Data and Key Metrics Changes - Revenue for Q2 2025 reached $271 million, representing a 15% year-over-year growth with an adjusted EBITDA margin of 42% [11][26] - Adjusted EBITDA increased by 20% year-over-year to $113 million, driven by revenue growth and a shift to higher-margin provider solutions [28] - The company raised its full-year revenue guidance to a range of $1.03 billion to $1.042 billion, reflecting a 10% year-over-year growth [30] Business Line Data and Key Metrics Changes - Subscription revenue increased by 17% year-over-year to $131 million, while volume-based revenue grew by 14% year-over-year to $138 million [27] - The number of clients generating more than $100,000 in trailing twelve-month revenue increased by 14% year-over-year to 1,268 [17] Market Data and Key Metrics Changes - The company noted a strong demand for its AI-powered software platform as providers face margin pressures and workforce shortages [11][12] - Waystar's net revenue retention rate was 115%, benefiting from rapid onboarding of clients affected by a competitor's cyber event [26] Company Strategy and Development Direction - The acquisition of Iodine Software is expected to expand Waystar's total addressable market by over 15% and enhance its product roadmap [8][9] - Waystar aims to lead in automating the revenue cycle and maximizing reimbursement for healthcare providers [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience against potential Medicaid funding cuts, estimating less than a 1% revenue impact from a hypothetical 15% reduction in Medicaid funding [13][87] - The company is optimistic about the demand environment, citing strong provider interest in efficiency and technology adoption [54] Other Important Information - Waystar was recognized as the best overall healthcare payments solution provider by MedTech Breakthrough [23] - The company added two new independent board members to strengthen its governance [24] Q&A Session Summary Question: Impact of client migration post-cyber attack on revenue - Management indicated that the year-over-year benefit from client migration has normalized, and there were no notable impacts in Q2 [34][35] Question: Recurring nature of volume-based revenue from large clients - Management expects that volume-based revenue from newly onboarded large clients will become recurring as contracts mature [42][46] Question: Drivers behind the sequential increase in subscription revenue - Management attributed the growth to strong performance in provider solutions and continued adoption of subscription services [50][57] Question: Volume growth and digital payment penetration - Management noted that higher utilization and digital payment solutions are driving volume growth, with a good mix from both patient payment and provider solutions [60][64] Question: AI's impact on client demand and revenue - Management highlighted that AI is embedded in their solutions, significantly improving claim processing and denial prevention [72][73] Question: Analysis of Medicaid funding changes and their impact - Management reassured that the diverse client base insulates the company from significant impacts due to funding changes, with alternative solutions available to providers [84][87] Question: Mid-cycle opportunities and AI's role - Management emphasized the potential of AI in mid-cycle revenue cycle management, particularly through the acquisition of Iodine [101][102]
Palantir Is Rapidly Increasing Its Presence In Healthcare
Forbes· 2025-07-30 13:15
Palantir has quickly become one of the most prominent names in the AI race. AFP via Getty Images Last month, recent Wall Street AI darling Palantir announced a new partnership with Teletracking to use its AI suite in conjunction with the latter's platform to optimize healthcare operations and organizational decision-making capabilities. Palantir's Foundry and AIP systems will be integrated with Teletracking's OperationIQ platform in order to: Alex Karp, CEO of Palantir, explains that this partnership repres ...
Treatment.com AI Engages Market Maker
GlobeNewswire News Room· 2025-07-29 21:32
Group 1 - Treatment.com AI Inc. has engaged Independent Trading Group (ITG) for market-making services to enhance liquidity and maintain a reasonable market for its shares on the Canadian Securities Exchange (CSE) [1][2] - ITG will receive a monthly compensation of CAD $5,500, with the agreement initially set for one month and renewable monthly unless terminated with 30 days' notice [2] - ITG is a Toronto-based dealer-member specializing in market making and liquidity provision, established in 1992, and utilizes proprietary technology for high-quality execution services [3] Group 2 - Treatment.com AI is focused on improving healthcare through AI and clinical practices, having developed the Global Library of Medicine (GLM) with input from healthcare professionals [4] - The GLM includes over 10,000 expert medical reviews, providing clinical information, recommended tests, and billing codes to support healthcare professionals and reduce their administrative burden [4] - The platform aims to enhance patient care and support disenfranchised communities by allowing healthcare professionals to spend more time with patients [4]
Treatment.com AI Engages Market Maker
Globenewswire· 2025-07-29 21:32
Core Points - Treatment.com AI Inc. has engaged Independent Trading Group (ITG) for market-making services to enhance liquidity and maintain a reasonable market for its shares [1][2] - ITG will receive a monthly compensation of CAD $5,500, with the agreement set for an initial term of one month and automatic renewals unless terminated [2] - ITG is a Toronto-based dealer-member specializing in market making and liquidity provision, established in 1992 [3] Company Overview - Treatment.com AI Inc. utilizes AI and clinical best practices to address inefficiencies in the healthcare sector [4] - The company has developed the Global Library of Medicine (GLM), which includes over 10,000 expert medical reviews to support healthcare professionals [4] - The GLM aims to reduce administrative burdens for healthcare providers and improve patient care quality, while also including disenfranchised communities [4]
Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution
Globenewswire· 2025-07-29 20:30
Core Insights - Counterpart Health, Inc. has appointed Vicky Bruner as Vice President of Operations to lead critical functions as the company scales to meet growing demand from payors and providers nationwide [1][2] - Bruner's experience in provider enablement and healthcare systems is expected to be invaluable for Counterpart's expansion and operational readiness [3] Company Overview - Counterpart Health is a subsidiary of Clover Health Investments, Corp. and operates as an AI-powered physician enablement platform [4] - The flagship software platform, Counterpart Assistant, aims to improve plan performance and clinical outcomes for Medicare members through proprietary AI technology [4] Leadership and Experience - Vicky Bruner previously served as Vice President of Network Performance at Optum Care Network, where she led risk operations and improved quality performance across Medicare and Medicaid populations [3] - Her background in driving P&L performance and aligned execution at scale positions her well for Counterpart's next phase of growth [3] Product and Impact - Counterpart Assistant provides clinical insights to primary care providers, reducing administrative work and enhancing patient outcomes [4] - Clover Health has published data demonstrating the technology's positive impact on Medication Adherence, Congestive Heart Failure, and the management of Diabetes and Chronic Kidney Disease [4]
HealthLynked Launches New Enterprise Healthcare Solutions Website and Upgraded Provider Directory to Expand Strategic Value Across the Healthcare Market
Globenewswire· 2025-07-28 11:35
Core Insights - HealthLynked Corp. has launched a newly designed Enterprise Healthcare Solutions Website and enhanced its consumer-facing provider directory, positioning itself as a key technology partner in the healthcare sector [1][2]. Group 1: New Website Launch - The new website serves as a dedicated platform for HealthLynked's commercial partners, showcasing tailored solutions for various stakeholders in the healthcare ecosystem [2]. - Dr. Michael Dent, CEO of HealthLynked, emphasized that the website reflects the company's expanding role and commitment to scalable solutions that improve healthcare outcomes and reduce costs [2][4]. Group 2: Enhanced Provider Directory - Major upgrades to the national provider directory have been implemented to enhance user experience, providing patients with more flexibility and transparency in selecting providers [3][6]. - The improvements aim to empower patients with smarter tools to manage their healthcare needs effectively [3][4]. Group 3: Strategic Vision and Commitment - The combination of the new website and upgraded provider directory demonstrates HealthLynked's commitment to innovation and strengthening strategic relationships within the healthcare landscape [4]. - The company continues to invest in technology that supports personalized patient care and enterprise-scale efficiency [4][5]. Group 4: Company Overview - HealthLynked Corp. is transforming healthcare through a cloud-based platform that connects patients and providers, offering secure medical record management, AI-driven insights, and a robust provider directory [5]. - The company provides various services tailored to insurance carriers, pharmaceutical companies, advertising firms, ACOs, healthcare networks, and large employers, focusing on improving access, cost savings, and coordinated care [5].
Treatment.com AI Announces Non-Brokered Private Placement of up to C$3 million of Special Warrants and Units
GlobeNewswire News Room· 2025-07-25 20:01
Core Viewpoint - Treatment.com AI Inc. is initiating a non-brokered private placement to raise up to C$3 million due to strong interest from investors, offering special warrants and units at C$0.50 each [1][5]. Group 1: Offering Details - The offering consists of special warrants and units, with each unit comprising one common share and one common share purchase warrant [1]. - Each warrant allows the holder to acquire one share at C$0.75 for 12 months following issuance [1]. - Special warrants will automatically convert into units on the earlier of the filing of a prospectus supplement or four months and one day after issuance [2]. Group 2: Use of Proceeds - Proceeds from the offering will be utilized for working capital purposes [5]. Group 3: Conditions and Fees - The offering is expected to close by August 18, 2025, and is subject to necessary approvals, including from the Canadian Securities Exchange [5]. - The company may pay a finder's fee of up to 8% of gross proceeds and issue broker warrants equal to 8% of the number of special warrants and/or units sold [4]. Group 4: Company Overview - Treatment.com AI is focused on improving healthcare through AI and best clinical practices, with a comprehensive healthcare AI engine known as the Global Library of Medicine (GLM) [7]. - The GLM provides clinical information and support to healthcare professionals, helping to reduce administrative burdens and improve patient care [7].